And here is Joe during the Q&A on the 10/29/2019 conf

Quote:

Joe: Well, we'll apply for the NASDAQ deal, yes. Just think about it in terms of
this: when we spin out NuGenerex Immuno-Oncology, there is absolutely no
hair on that. It's been audited under on Generex for well over ten years; those
Generex Investor Call October 29, 2019
Page 17 of 43
audits are just a split out from the Generex overall audits. So, there's a time
advantage there.
We acquired an existing, operating company--not a shell--that is list-ready to
list out the next day, if you fit all the criteria. The only criteria that we need
for a NASDAQ listing is our going concern, which is all the cash--well, oneyear cash burn that will allow us to do operations for one year. The
NASDAQ wants to see that you have the going concern on. That's the only
big thing that we have there, and of course with all the great stuff that
NuGenerex Immuno-Oncology has going on, there's no shortage of money
that will be raised to get it to a NASDAQ listing.
But again, IPO takes a long time; NASDAQ shell, 13 months. I mean a shell
is 13 months from the time you acquired it to the time you can even start
thinking about uplisting. A NASDAQ vehicle, you give up a lot of the
company to get one of those, and I don't want to do that because of the high
value that NuGenerex Immuno-Oncology represents, so that is out.
So, the only other quick, easy, and best way--and obtaining all 100 percent
within Generex-- is to acquire an operating vehicle. And an operating vehicle
that does not have shell status. That's what we acquired, that's what we're
going to be merging into, and that will immediately stop the clock on when
we can list this to a NASDAQ exchange.
So, it's the quickest, it's the fastest, and it's the best way, in my opinion, to do
that--and to give our shareholders immediate value as well as the hundreds
and hundreds of millions I believe we're going to add to the Generex balance
sheet, which is phenomenally huge. Our balance sheet once we take it public,
will change dramatically.